Interferon γ, IL2, IL4, IL10 and TNFα Secretions in Multiple Sclerosis Patients Treated with an Anti-CD4 Monoclonal Antibody

References

• Hillert J. Human leukocyte antigen studies in multiple sclerosis. Ann. Neurol. 1994; 36: 15–17
   Google Scholar
• Hafler D. A., Weiner H. L. Multiple sclerosis: a CNS and systemic autoimmune disease. Immunol. Today 1989; 10: 104–07
   PubMedGoogle Scholar
• IFNβ Multiple Sclerosis Study Group. Interferon beta-Ibis effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 1993; 43: 655–61
   PubMed Web of Science ®Google Scholar
• Jacobs L. D., Cookfair D. L., Rudick R. A., Herndon R. M., Richert J. R., Salazar A. M., et al. Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann. Neurol. 1996; 39: 285–94
   PubMed Web of Science ®Google Scholar
• Lindsey J. W., Hodgkinson S., Mehta R., Mitchell D., Enzmann D., Steinman L. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann. Neurol 1994; 36: 183–89
   PubMed Web of Science ®Google Scholar
• Llewellyn-Smith N., Lai M., Miller D. H., Rudge P., Thompson A. J., Cuzner M. L. Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM- T412. Neurology 1997; 48: 810–16
   PubMed Web of Science ®Google Scholar
• Racadot E., Wendling D., Rumbach L., Widjenes J., Herve P. Current concepts in the treatment of autoimmune diseases with monoclonal antibodies. Clin. Immunother. 1994; 1: 199–208
   Google Scholar
• Racadot E., Rumbach L., Bataillard M., Galmiche J., Henlin J. L., Truttmann M., et al. Treatment of multiple sclerosis with anti-CD4 monoclonal antibody. J. Autoimmun. 1993; 6: 771–86
   PubMed Web of Science ®Google Scholar
• Rumbach L., Racadot E., Armspach J. P., Namer I. J., Bonneville J. F., Wijdenes J., et al. Biological assessment and MRI monitoring of the therapeutic efficacy of a monoclonal anti-T CD4 antibody in multiple sclerosis patients. Multiple Sclerosis 1996; 1: 207–12
   PubMedGoogle Scholar
• Giovannoni G., Hartung H. P. The immunopathogenesis of multiple sclerosis and Guillain-Barré syndrome. Curr. Opin. Neurol. 1996; 9: 165–77
   PubMed Web of Science ®Google Scholar
• Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 1997; 120: 865–916
   PubMed Web of Science ®Google Scholar
• Hirsch R. L., Panitch H. S., Johnson K. M. Lymphocytes from MS patients produce elevated levels of IFNγ in vitro. J. Clin. Immunol. 1985; 5: 386–92
   PubMed Web of Science ®Google Scholar
• Bansil S., Cook S. D., Rohowsky-Kochan C. Multiple sclerosis: immune mechanism and update on current therapies. Ann. Neurol. 1995; 37: S87–S101
   PubMedGoogle Scholar
• Peter J. B., Boctor F. N., Tourtelotte W. W. Serum and CSF levels of IL-2, sIL-2R, TNFα and IL-1β in chronic progressive multiple sclerosis: expected lack of clinical utility. Neurology 1991; 41: 121–23
   PubMed Web of Science ®Google Scholar
• Gallo P., Piccino M. G., Tavolato B. A longitudinal study on IL-2, sIL2R, IL-4 and IFN7 in multiple sclerosis CSF and serum. J. Neurol. Sci. 1991; 101: 227–32
   PubMed Web of Science ®Google Scholar
• Freedman M. S., Muth K. L., Trotter J. L., Yoshizawa N., Antel J. P. Prospective serial analysis of interleukin-2 and soluble interleukin-2 receptor in relapsing-remitting multiple sclerosis. Neurology 1992; 42: 1596–601
   PubMed Web of Science ®Google Scholar
• Van Noort J. M., Nagelkerken L., Boog C. J.P. Immune intervention strategies in EAE. Int. MSJ 1994; 1: 43–49
   Google Scholar
• Corrcale J., Gilmore W., McMillan M., Li S., McCarthy K., Le T., Weiner L. P. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T-cell clones during the course of multiple sclerosis. J. Immunol 1995; 154: 2959–68
   PubMed Web of Science ®Google Scholar
• Ragheb S., Lidak R. P. Multiple sclerosis: genetic- background versus environment. Ann. Neurol. 1993; 34: 509–10
   PubMed Web of Science ®Google Scholar
• Glabinski A., Mirecka M., Pokoca L. Tumor necrosis factor but not lymphotoxin is overproduced by blood mononuclear cells in multiple sclerosis. Acta Neurol. Scand. 1995; 91: 276–79
   PubMed Web of Science ®Google Scholar
• Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., Luer W., Poser S. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 1994; 44: 1523–26
   PubMed Web of Science ®Google Scholar
• Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., et al. Tumor necrosis factor ft messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann. Neurol. 1995; 37: 82–8
   PubMed Web of Science ®Google Scholar
• Mc Farland H. F. Complexities in the treatment of autoimmune disease. Science 1996; 274: 2037–8
   PubMed Web of Science ®Google Scholar
• Genain C. P., Abel K., Belmar N., Villinger F., Rosenberg D. P., Linington C., et al. Late complications of immune deviation therapy in a nonhuman primate. Science 1996; 274: 2054–6
   PubMed Web of Science ®Google Scholar
• Ramanathan S., de Kozak Y., Saoudi A., Goureau O., Van der Meide P. H., Druet P., Bellon B. Recombinant IL4 aggravates experimental autoimmune uveoretinitis in rats. J. Immunol. 1996; 157: 2209–15
   PubMed Web of Science ®Google Scholar
• Van Oosten B. W., Lai M., Hodgkinson S., Barkhof F., Miller D. H., Moseley I. F., et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled. MR-monitored phase II trial. Neurology 1997; 49: 351–7
   PubMed Web of Science ®Google Scholar